Emmaus Life Sciences, Inc. (EMMA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Torrance, CA, United States. The current CEO is Willis C. Lee.
EMMA has IPO date of 2000-05-09, 34 full-time employees, listed on the Other OTC, a market capitalization of $652.75K.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
